Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • The American Association of Immunologists  (4)
  • 1
    In: The Journal of Immunology, The American Association of Immunologists, Vol. 191, No. 5 ( 2013-09-01), p. 2604-2613
    Abstract: In vitro studies identified Y-box–binding protein (YB)-1 as a key regulator of inflammatory mediators. In this study, we observed increased levels of secreted YB-1 in sera from sepsis patients. This led us to investigate the in vivo role of YB-1 in murine models of acute peritonitis following LPS injection, in sterile renal inflammation following unilateral ureteral obstruction, and in experimental pyelonephritis. LPS injection enhanced de novo secretion of YB-1 into the urine and the peritoneal fluid of LPS-treated mice. Furthermore, we could demonstrate a significant, transient upregulation and posttranslational modification (phosphorylation at serine 102) of YB-1 in renal and inflammatory cells. Increased renal cytoplasmic YB-1 amounts conferred enhanced expression of proinflammatory chemokines CCL2 and CCL5. Along these lines, heterozygous YB-1 knockout mice (YB-1+/d) that display 50% reduced YB-1 levels developed significantly lower responses to both LPS and sterile inflammation induced by unilateral ureteral obstruction. This included diminished immune cell numbers due to impaired migration propensities and reduced chemokine expression. YB-1+/d mice were protected from LPS-associated mortality (20% mortality on day 3 versus 80% in wild-type controls); however, immunosuppression in YB-1+/d animals resulted in 50% mortality. In conclusion, our findings identify YB-1 as a major, nonredundant mediator in both systemic and local inflammatory responses.
    Type of Medium: Online Resource
    ISSN: 0022-1767 , 1550-6606
    RVK:
    RVK:
    Language: English
    Publisher: The American Association of Immunologists
    Publication Date: 2013
    detail.hit.zdb_id: 1475085-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    The American Association of Immunologists ; 2011
    In:  The Journal of Immunology Vol. 186, No. 1_Supplement ( 2011-04-01), p. 163.8-163.8
    In: The Journal of Immunology, The American Association of Immunologists, Vol. 186, No. 1_Supplement ( 2011-04-01), p. 163.8-163.8
    Abstract: Recent studies in humans have suggested that females may be more susceptible to allergic asthma than male. In addition, studies in Balb/c mice revealed that females have higher serum IgE levels, Th2 cytokines and an increased number of CD4+ T-cells. Mice lacking the Th1-specific transcriptional factor T-bet (T-bet-/-) show a severe phenotype of asthma with increased AHR, eosinophils and Th2 type cytokines in their airways. We therefore analyzed gender specific immune-responses in T-bet-/- mice in a murine model of allergic asthma. To this aim, we first looked at the Th2 inducing cytokine IL-6 and found it induced in the airways of naïve T-bet-/- mice. IL-6 inhibits T regulatory cells and together with TGFβ1 induces Th17 cells. We then studied the expression of different cytokines involved in the development of the Th17-pathway in a gender dependent manner. We found that total lung cells isolated from asthmatic female T-bet-/- mice release increased levels of IL-6, TGFβ1 and IL-17 compared to the male littermates. Consistently, in these mice, other cytokines of the Th17-pathway like IL-23 and IL-21 were also found induced in the lung of female T-bet-/- mice as compared to the levels measured in the lung of males. These results might explain why females are more susceptible than males to some aspects of asthma and therefore gender specific studies in asthma might help to better design therapies for this disease.
    Type of Medium: Online Resource
    ISSN: 0022-1767 , 1550-6606
    RVK:
    RVK:
    Language: English
    Publisher: The American Association of Immunologists
    Publication Date: 2011
    detail.hit.zdb_id: 1475085-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    The American Association of Immunologists ; 2012
    In:  The Journal of Immunology Vol. 188, No. 1_Supplement ( 2012-05-01), p. 125.9-125.9
    In: The Journal of Immunology, The American Association of Immunologists, Vol. 188, No. 1_Supplement ( 2012-05-01), p. 125.9-125.9
    Abstract: Immunotherapy (IT) is one of the most effective therapies for increasing allergic diseases worldwide including allergic asthma. Previously, we have established a murine model of subcutaneous IT for experimental allergic asthma. We demonstrated that main components of allergic asthma induced by T-bet deficiency such as airway hyperresponsiveness could be ameliorated. These data suggested that the molecular mechanism induced by IT is T-bet independent. To analyze this yet unknown mechanism we started to investigate IL-6 expression in this model. IL-6 is a cytokine produced by several cell types of the innate as well as adaptive immune system. We previously described that IL-6 is increased in the lung cells of T-bet deficient (T-bet-/-) naïve mice as compared to wild type littermates. In a murine model of allergic asthma we found that IL-6 is significantly down-regulated in the lung of T-bet-/- mice that have been treated according to the IT protocol. Likewise, we found that the newly discovered cytokine IL-33, of the IL-1 family, is significantly up-regulated in the lung of T-bet-/- mice in experimental asthma and down-regulated after IT. In conclusion we discovered that the protective mechanism of the IT comprises down-regulation of IL-6 and IL-33. These findings could be considered for future novel therapy for allergic asthma.
    Type of Medium: Online Resource
    ISSN: 0022-1767 , 1550-6606
    RVK:
    RVK:
    Language: English
    Publisher: The American Association of Immunologists
    Publication Date: 2012
    detail.hit.zdb_id: 1475085-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    The American Association of Immunologists ; 2011
    In:  The Journal of Immunology Vol. 186, No. 1_Supplement ( 2011-04-01), p. 48.13-48.13
    In: The Journal of Immunology, The American Association of Immunologists, Vol. 186, No. 1_Supplement ( 2011-04-01), p. 48.13-48.13
    Abstract: IL17A is a cytokine mainly produced by Th17 cells. The function of the Th17 cell lineage in lung cancer remains to be elucidated. In our study we found increased expression of the Th17 transcription factors RORα4 and RORγt and the cytokine IL-17A in the lungs of patients with lung adenocarcinoma compared to healthy control tissue. In lung cancer tissues IL-17A inversely correlated with the Th1 specific factor T-bet. Targeting of IL-17A in a murine model of lung adenocarcinoma by intranasal application of anti IL17A antibodies resulted in reduction of lung tumor load and prolonged survival of wild-type mice. Studies in T-bet (-/-) mice revealed up-regulation of lung IL-23/IL-23-R and IL-17A/IL-17A-R in T cells infiltrating the tumor. Local anti-IL-17A antibodies treatment improved (50%) survival in treated T-bet (-/-) mice, reduced the number of IL-17R expressing lung CD4+ T cells, induced the number of natural killer cells and CD8+ T cells producing IFNγ compared to wild type littermates-bearing tumor and treated in the same way. These data might indicate that local anti IL-17A antibody therapy could be successful for the treatment of lung tumor also in the absence of T-bet.
    Type of Medium: Online Resource
    ISSN: 0022-1767 , 1550-6606
    RVK:
    RVK:
    Language: English
    Publisher: The American Association of Immunologists
    Publication Date: 2011
    detail.hit.zdb_id: 1475085-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages